1.1.1 Specimens
120 experience group blood samples were from 48 COVID-19 patients
(confirmed by positive nucleic acid test, including 2 dead patients, 17
asymptomatic infected patients) in Loudi Center for Disease Control and
Prevention, time from onset to discharge of 3 of other 29 patients were
unknown, of the other 26 patients were shown in Figure 1; 88 control
group blood samples were from The First Hospital of Hunan University of
Chinese medicine (53 patients with malignant tumor, blood system
disease, rheumatic immune system disease and other diseases that
increase the level of inflammatory factors, and 35 healthy people). 75
experience group blood samples were from males and 35 from females, the
age distribution of COVID-19 patients we collected were shown in Figure
2. All the selected cases and their families had given their informed
consent.
Instruments and reagents
IL-10, IL-1β, IL-6, MCP-1, TNF-α, IP-10 and IL-4 test kits and their
standard were purchased from Human diagnostic products (Beijing) Co.,
Ltd., the minimal detectable concentrations for they were 0.0225,
0.0355, 0.0600, 0.0655, 0.0386, 0.0102 and 0.1800 pg/mL, count the
result which lower than the minimal detectable concentrations as half of
the minimal detectable concentrations; all reagents had both good
repeatability (CV < 10%) and specificity. TECAN 200-8 were
purchased from TECAN (Shanghai) trading company. SAS-CoV-2 antibody test
kit (colloidal gold immunochromtographic assay, Guangzhou Wanfu
Biotechnology Co., Ltd.) and SAS-CoV-2 IgM and IgG antibody test kit
(chemiluminescent immunoassay, purchased from Shenzhen Yahuilong
Biotechnology Co., Ltd.) were selected for serum antibody test.